Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2432
{ "count": 24528, "next": "http://api.gregory-ms.com/articles/?format=api&page=2433", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2431", "results": [ { "article_id": 217, "title": "Serum Based miRNA as a Diagnostic Biomarker for Multiple Sclerosis: a Systematic Review and Meta-Analysis", "summary": "<div><p>Immunol Invest. 2021 Mar 4:1-16. doi: 10.1080/08820139.2021.1887888. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">This systematic review and meta-analysis aimed to identify deferentially expressed serum miRNAs in multiple sclerosis patients and to evaluate their diagnostic value in multiple sclerosis diagnosis. Studies were identified on PubMed, Google scholar and Saudi digital library up to 30 September 2019. Articles that examined miRNA expression level in MS patients compared to healthy control group were included in the review and the data were extracted by three independent author. The comprehensive Meta-Analysis version 3 software was used for meta-analysis and heterogeneity of studies was identified according to I2 value. Our literatures search identified 9 eligible articles concerning the serum miRNA as a diagnostic biomarker for multiple sclerosis in comparison to healthy control group. 19 serum miRNAs differentially expressed in MS patients were identified (8 downregulated, 11 upregulated and 1 with discordant result). In publications that provided information on specific miRNA diagnostic value, the pooled AUC was 72% (95% CI 0.65-0.78, <i>p</i>-value 0.00) for the overall multiple sclerosis patients and primary progressive MS (PPMS) (95% CI 0.66-0.78 <i>p</i>-value 0.00). A miRNA panel of four miRNAs showed high sensitivity (73%) and specificity (68%) in distinguishing multiple sclerosis from control groups. When using single miRNA (miR-145), the sensitivity increased to 79% and the specificity to 87%. The available data from the literature and this meta-analysis suggests the potential use of serum miRNA as biomarkers for early diagnosis of MS with high sensitivity and specificity in distinguishing multiple sclerosis subtypes from healthy controls.<b>Abbreviation</b>: MS: Multiple sclerosis; IDD: inflammatory demyelinating diseases; RRMS: relapsing-remitting Multiple sclerosis; PPMS: primary progressive Multiple sclerosis; SPMS: secondary progressive Multiple sclerosis; NMO: Neuromyelitis optica; miRNA: microRNA; ECmiRNA: extracellular microRNA; AUC: Area Under the Curve; ROC: Receiver Operator Characteristic.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33660581/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304135644&v=2.14.2\">33660581</a> | DOI:<a href=\"https://doi.org/10.1080/08820139.2021.1887888\">10.1080/08820139.2021.1887888</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33660581/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-12-19T00:16:08.328000Z", "source": "PubMed", "publisher": "Informa UK Limited", "container_title": "Immunological Investigations", "authors": [ { "author_id": 240905, "given_name": "Samar A.", "family_name": "Zailaie", "ORCID": null, "country": null }, { "author_id": 240906, "given_name": "Jumana Jamal", "family_name": "Siddiqui", "ORCID": null, "country": null }, { "author_id": 240907, "given_name": "Rawan Mansour", "family_name": "Al Saadi", "ORCID": null, "country": null }, { "author_id": 240908, "given_name": "Dalia Mohammad", "family_name": "Anbari", "ORCID": null, "country": null }, { "author_id": 163169, "given_name": "Amani", "family_name": "S. Alomari", "ORCID": "http://orcid.org/0000-0002-5230-4079", "country": null }, { "author_id": 240910, "given_name": "Edward James", "family_name": "Cupler", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T18:56:45Z", "noun_phrases": [ "Serum Based miRNA", "a Diagnostic Biomarker", "Multiple Sclerosis", "a Systematic Review", "Meta-Analysis" ], "doi": "10.1080/08820139.2021.1887888", "access": "restricted", "takeaways": " The pooled AUC was 72% (95% CI 0.65-0.78, p-value 0.78) for MS patients and primary progressive MS (PPMS) A miRNA panel of four miRNAs showed high sensitivity (73%) and specificity (68%) in distinguishing multiple sclerosis from control groups . When using single miRNA (miR-145), the sensitivity increased to 79% and the specificity to 87%.", "categories": [] }, { "article_id": 216, "title": "The gelsolin level in patients with primary Sjogren's syndrome", "summary": "<div><p>Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):2072-2078. doi: 10.26355/eurrev_202102_25112.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: Gelsolin (GSN) is a multifunctional protein that can regulate cell proliferation, apoptosis, inflammation and infection. GSN has been reported to be involved in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS) and many other diseases. The role of GSN in primary Sjogren's syndrome (pSS) remains still unclear. The aim of this study is to investigate the changes of GSN level in serum and whole blood cells of pSS patients and evaluate the relationship between GSN and fatigue or other clinical indicators.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">PATIENTS AND METHODS: The cross-sectional study included 47 pSS patients (1 male and 46 females, average age: 52.83±12.63 years) and 51 healthy controls (all females, average age: 50.61±9.86 years). The patients were collected from the Second Affiliated Hospital of Harbin Medical University, China, without the age and sex differences. The levels of GSN in serum of pSS patients and the healthy controls were measured by Western blotting. The sequencing gene expression omnibus (GEO) data from National Center for Biotechnology Information (NCBI) about GSN levels in the whole blood cells of pSS patients and the healthy controls were analyzed by R language.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Compared with healthy controls, the level of GSN was significantly decreased in the serum of pSS patients (98.89 ± 28.94 vs. 131.6 ± 37.1 µg/ml, p<0.001). The expression of GSN in the whole blood cells of pSS patients was significantly lower than that in the healthy controls (6.4 ± 0.19 vs. 6.6 ± 0.17, p<0.01). Compared to non-fatigued pSS patients, the level of GSN was down-regulated in serum (85.69 ± 27.08 vs. 111.52 ± 24.71 µg/ml, p<0.01) and whole blood cells (6.43 ± 0.18 vs. 6.58 ± 0.21, p<0.001) in fatigue pSS patients. However, there was no significant correlation between the level of GSN and EULAR Sjogrens syndrome disease activity index (ESSDAI) in pSS patients (p=0.73).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: GSN is decreased in serum and whole blood cells of pSS patients, and it is much lower in fatigue patients than that in non-fatigue patients. The correlation between the level of GSN and ESSDAI was not significant in pSS patients.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33660820/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304135644&v=2.14.2\">33660820</a> | DOI:<a href=\"https://doi.org/10.26355/eurrev_202102_25112\">10.26355/eurrev_202102_25112</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33660820/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-02T00:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T18:56:45Z", "noun_phrases": [ "The gelsolin level", "patients", "primary Sjogren's syndrome" ], "doi": "10.26355/eurrev_202102_25112", "access": "restricted", "takeaways": " Gelsolin (GSN) is a multifunctional protein that can regulate cell proliferation, apoptosis, inflammation and infection . The role of GSN in primary Sjogren's syndrome (pSS) remains still unclear . GSN is decreased in serum and whole blood cells of pSS patients .", "categories": [] }, { "article_id": 218, "title": "The relationship between vitamin D levels and cognitive impairment in patients with multiple sclerosis", "summary": "<div><p>Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):2021-2030. doi: 10.26355/eurrev_202102_25105.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: Neurocognitive impairment is one of the most common manifestations of multiple sclerosis (MS). However, the pathophysiology of this issue is still poorly understood. The objective of this study is to investigate the relationship between vitamin D levels and cognitive function in patients with MS as assessed by the Cambridge Neuropsychological Test Automated Battery (CANTAB).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">PATIENTS AND METHODS: This was a cross-sectional, case-control study; the subjects were 39 Saudi patients diagnosed with MS. For all participants, demographic information, including age, sex, and educational level, was collected. Participants were also evaluated using the disease steps scale and the PHQ-9 scale. Their vitamin D levels were assessed, and the participants completed a computerized cognitive assessment using the CANTAB.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: From the total sample of 39 patients with MS, 31 (79.5%) were female. Physical disability due to MS was insignificant in 25 (64.1%) of the subjects and significant in 14 (35.9%). Seventeen (43.6%) of the participants had normal vitamin D levels; 22 (56.4%) had low vitamin D levels. The MS patients had lower MOT mean errors than the control group, and this difference was statistically significant (t = -4.313, p < 0.01). Moreover, the scores of the two groups for all subcategories of the memory domain were different at statistically significant levels. Furthermore, the control group had higher PAL total errors (adjusted), PAL total errors (6 shapes, adjusted), and PRM percent correct than the MS patients (p < 0.01). The control group also achieved lower scores on SWM between errors and SWM strategy than the MS patients (p < 0.01). The MOT mean error was found to correlate with the disease steps score (r = 0.394, p < 0.05) and with significant physical disability (r = 0.457, p< 0.01). In the memory domain, PAL total errors (adjusted) correlated with age (r = 0.381, p < 0.05), SWM between errors correlated with age at onset of disease (r = 0.345, p < 0.05), and vitamin D level (r = 0.335, p < 0.05) and SWM strategy correlated with the number of relapses in the past 12 months (r = -0.355, p < 0.05).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: Cognitive performance was impaired in patients with MS. Vitamin D deficiency, a potentially modifiable risk factor, independently predicted cognitive impairment in MS patients.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33660814/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304135644&v=2.14.2\">33660814</a> | DOI:<a href=\"https://doi.org/10.26355/eurrev_202102_25105\">10.26355/eurrev_202102_25105</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33660814/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-02T00:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T18:56:45Z", "noun_phrases": [ "The relationship", "vitamin D levels", "cognitive impairment", "patients", "multiple sclerosis" ], "doi": "10.26355/eurrev_202102_25105", "access": "restricted", "takeaways": " Neurocognitive impairment is one of the most common manifestations of multiple sclerosis . Vitamin D deficiency, a potentially modifiable risk factor, independently predicted cognitive impairment in MS patients .", "categories": [] }, { "article_id": 213, "title": "Poster Abstracts from the 10th International Symposium on Gait and Balance in Multiple Sclerosis: The Role of Fatigue and Fatigability", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):45-46. doi: 10.7224/1537-2073-23.1.45. Epub 2021 Feb 23.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658906/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658906</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906032/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906032</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073-23.1.45\">10.7224/1537-2073-23.1.45</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658906/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "the 10th International Symposium", "Gait", "Balance", "Multiple Sclerosis", "The Role", "Fatigue", "Fatigability" ], "doi": "10.7224/1537-2073-23.1.45", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 212, "title": "Editorial", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):iv. doi: 10.7224/1537-2073-23.1.iv. Epub 2021 Feb 23.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658907/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658907</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906026/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906026</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073-23.1.iv\">10.7224/1537-2073-23.1.iv</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658907/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [ { "author_id": 254660, "given_name": "Francois", "family_name": "Bethoux", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Editorial" ], "doi": "10.7224/1537-2073-23.1.iv", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 203, "title": "Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "summary": "<div><p>Front Pharmacol. 2020 Nov 20;11:589146. doi: 10.3389/fphar.2020.589146. eCollection 2020.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><b>Background:</b> Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the United States FDA. As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety concerns caused by S1P<sub>3</sub> receptor activation. <b>Methods:</b> e systematically searched PUBMED, EMBASE database, and Cochrane Library database to identify randomized controlled trials (RCTs) from inception to June 28, 2020. Trials were considered eligible if they 1) were randomized clinical trials (RCTs); 2) enrolled adult participants diagnosed with Relapsing-remitting MS; 3) compared ozanimod with placebo or any other approved DMDs that evaluated in phase III or phase II clinical trials; 4) enrolled over 100 participants; 5) provided any available information for predefined primary or secondary outcomes. <b>Results:</b> 2917 participants from three high-quality, multi-centered randomized clinical trials were pooled in our analysis. We found that using ozanimod was significantly associated with the reduction of the annualized relapse rate during the treatment period (RR, -0.10 [95% CI, -0.15, -0.06]). Also, the decreased number of gadolinium-enhancing lesions at the end of the trial was relative to the treatment of ozanimod (ozanimod, 0.29; control, 0.65; RR, -0.20 [95% CI, -0.34, -0.06]). Compared with patients in the control group, the number of new or enlarging T2 lesions over the treatment period decreased in patients treated with ozanimod (ozanimod, 1.82; control, 3.55; RR, -1.12 [95% CI, -1.52, -0.71]). As to the safety endpoints, patients in the ozanimod group reported a lower rate of adverse events (ozanimod, 66.03%; control, 77.07%; RR, 0.64 [95% CI, 0.43, 0.95]). Similar incidence of infection-related TEAEs was found across treatment groups (nasopharyngitis: ozanimod, 11.19%; control, 9.83%; RR, 1.10 [95% CI, 0.77-1.57]; urinary-tract infection: ozanimod, 3.81%; control, 2.97%; RR, 1.29 [95% CI, 0.83-2.00]). No case of macular edema was noted as well as second-degree, type 2, or third-degree atrioventricular block. As for the subgroup analysis, compared with 0.5 mg ozanimod, 1 mg ozanimod is related with a significant reduction of the annualized relapse rate during the treatment period (1 mg ozanimod, 0.18; 0.5 mg ozanimod, 0.24; RR, 0.05 [95% CI, 0.01, 0.09])and a decreased number of new or enlarging T2 lesions over the treatment period (1 mg ozanimod,1.58; 0.5 mg ozanimod, 2.05; RR, 0.49 [95% CI, 0.19, 0.79]). No significant difference in causing adverse events between 1 and 0.5 mg was found. <b>Conclusions:</b> Our meta-analysis found that, with favorable safety performance, the use of ozanimod as a treatment of relapsing-remitting multiple sclerosis in adults was associated with a significant reduction of the annualized relapse rate during the treatment period, decreased number of gadolinium-enhancing lesions at the end of the trial, and lowered number of new or enlarging T2 lesions over the treatment period. Ozanimod 1 mg outperformed 0.5 mg dose in efficacy without increasing the risk of adverse events.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658933/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658933</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7919188/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7919188</a> | DOI:<a href=\"https://doi.org/10.3389/fphar.2020.589146\">10.3389/fphar.2020.589146</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658933/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2020-11-20T00:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Pharmacology", "authors": [ { "author_id": 308540, "given_name": "Yue", "family_name": "Sun", "ORCID": null, "country": null }, { "author_id": 308541, "given_name": "Yanbo", "family_name": "Yang", "ORCID": null, "country": null }, { "author_id": 272312, "given_name": "Zilan", "family_name": "Wang", "ORCID": null, "country": null }, { "author_id": 308542, "given_name": "Fan", "family_name": "Jiang", "ORCID": null, "country": null }, { "author_id": 272313, "given_name": "Zhouqing", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 174967, "given_name": "Zhong", "family_name": "Wang", "ORCID": "http://orcid.org/0000-0002-7342-0845", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Ozanimod", "Treatment", "Relapsing-Remitting Multiple Sclerosis", "Adults", "A Systematic Review", "Meta-Analysis", "Randomized Controlled Trials" ], "doi": "10.3389/fphar.2020.589146", "access": "open", "takeaways": " Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the U.S. FDA . The number of new or enlarging T2 lesions over the treatment period decreased in patients treated with ozanimod . No significant difference in causing adverse events between 1 and 0.5 mg was found .", "categories": [ { "category_id": 25, "category_description": "Ozanimod", "category_name": "Ozanimod", "category_slug": "ozanimod", "category_terms": [ "ozanimod", "zeposia" ], "article_count": 29 } ] }, { "article_id": 201, "title": "Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study", "summary": "<div><p>Neurol Sci. 2021 Mar 3. doi: 10.1007/s10072-021-05145-x. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: So far, a limited number of real-world evidence studies about the effectiveness and safety of alemtuzumab (ALM) have been published, some of them with a relatively small number of included patients. We aimed to study the efficacy and safety of ALM in real-world clinical practice in two MS centers in Slovenia and Croatia.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: This was a retrospective chart review of 71 consecutive patients with relapsing-remitting MS who were treated with ALM from 2015 till 2018. The following data were collected: gender, age at disease onset, disease duration at ALM initiation, previous disease modifying therapy, number of relapses, active MRI lesions, and EDSS in the year prior to ALM initiation and every year of follow-up.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: All patients completed the standard dosing schedule and were followed for a mean time of 3.2±1.1 years after the initiation of treatment. Complete data for the 2 years after treatment (relapses, EDSS, and MRI) were available for 48 patients, of which 14 (29.2%) achieved NEDA. Clinical NEDA was achieved in 38 out of 63 participants (60.3%). In year 1, 24 out of 57 (42.1%) patients achieved NEDA. In year 2, 26 out of 41 (63.4%) patients achieved NEDA. Lower EDSS prior to starting ALM was the only independent predictor of NEDA in a multivariable model. Adverse events occurred in 58 participants (84.1%), with no new safety signals identified.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: According to the data from our cohort of early active RRMS patients we conclude ALM efficacy remains high in the real-world clinical practice.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33660157/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33660157</a> | DOI:<a href=\"https://doi.org/10.1007/s10072-021-05145-x\">10.1007/s10072-021-05145-x</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33660157/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-11T00:00:00Z", "source": "PubMed", "publisher": "Springer Science and Business Media LLC", "container_title": "Neurological Sciences", "authors": [ { "author_id": 214271, "given_name": "Gregor", "family_name": "Brecl Jakob", "ORCID": "http://orcid.org/0000-0003-4998-5974", "country": "SI" }, { "author_id": 240781, "given_name": "Barbara", "family_name": "Barun", "ORCID": null, "country": null }, { "author_id": 203765, "given_name": "Sarah", "family_name": "Gomezelj", "ORCID": "http://orcid.org/0000-0001-8649-5435", "country": null }, { "author_id": 240782, "given_name": "Tereza", "family_name": "Gabelić", "ORCID": null, "country": null }, { "author_id": 240783, "given_name": "Saša", "family_name": "Šega Jazbec", "ORCID": null, "country": null }, { "author_id": 221943, "given_name": "Ivan", "family_name": "Adamec", "ORCID": "http://orcid.org/0000-0003-3873-6526", "country": null }, { "author_id": 240784, "given_name": "Alenka", "family_name": "Horvat Ledinek", "ORCID": null, "country": null }, { "author_id": 324648, "given_name": "Uroš", "family_name": "Rot", "ORCID": "http://orcid.org/0000-0002-2422-8670", "country": null }, { "author_id": 192760, "given_name": "Magdalena", "family_name": "Krbot Skorić", "ORCID": "http://orcid.org/0000-0002-1087-3732", "country": "HR" }, { "author_id": 161545, "given_name": "Mario", "family_name": "Habek", "ORCID": "http://orcid.org/0000-0002-3360-1748", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Effectiveness", "safety", "alemtuzumab", "the treatment", "active relapsing-remitting multiple sclerosis", "a multicenter, observational study" ], "doi": "10.1007/s10072-021-05145-x", "access": "restricted", "takeaways": " A limited number of real-world evidence studies about effectiveness and safety of alemtuzumab (ALM) have been published, some of them with a relatively small number of included patients .", "categories": [ { "category_id": 2, "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/", "category_name": "Alemtuzumab", "category_slug": "alemtuzumab", "category_terms": [ "alemtuzumab", "lemtrada" ], "article_count": 117 } ] }, { "article_id": 202, "title": "Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials", "summary": "<div><p>Front Neurol. 2021 Feb 15;11:574748. doi: 10.3389/fneur.2020.574748. eCollection 2020.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><b>Background:</b> Multiple sclerosis (MS), a disabling demyelinating disease of the central nervous system, is associated with cognitive impairment, spasticity, and fatigue. There are still no established guidelines on the management of MS-related sequela. Memantine has the potential to reduce glutamate toxicity, thereby reducing consequent cognitive impairment, spasticity, and fatigue. <b>Objectives:</b> This study aims to determine the efficacy and safety of memantine in preventing cognitive impairment, reducing spasticity and fatigue, and controlling disability in MS patients through a review of relevant randomized trials. <b>Methods:</b> MEDLINE, CENTRAL, Scopus, Embase, LILACS, ClinicalTrials.gov, and HERDIN were searched from inception to May 2020 for relevant trials. <b>Results:</b> The search yielded 203 articles; four studies were included in the analysis. Pooled evidence shows that memantine compared with placebo does not significantly improve PASAT, ASS, MFIS, and EDSS scores of patients with MS. Memantine is associated with mild adverse drug events such as dizziness, fatigue, and anxiety. <b>Conclusion:</b> There is not enough evidence to support the efficacy of memantine in preventing cognitive decline, controlling spasticity, reducing fatigue, and preventing disability. Future researches should consider the different MS subtypes, effect of co-administration of disease-modifying therapies, longer duration of administration, and more sensitive outcome measures to evaluate the potential benefit of memantine in MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658967/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658967</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7917060/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7917060</a> | DOI:<a href=\"https://doi.org/10.3389/fneur.2020.574748\">10.3389/fneur.2020.574748</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658967/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-15T00:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Neurology", "authors": [ { "author_id": 240763, "given_name": "Christian Wilson R.", "family_name": "Turalde", "ORCID": null, "country": null }, { "author_id": 240764, "given_name": "Adrian I.", "family_name": "Espiritu", "ORCID": null, "country": null }, { "author_id": 240765, "given_name": "Veeda Michelle M.", "family_name": "Anlacan", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Memantine", "Multiple Sclerosis", "A Systematic Review", "Meta-Analysis", "Randomized Trials" ], "doi": "10.3389/fneur.2020.574748", "access": "open", "takeaways": " Multiple sclerosis (MS) is a disabling demyelinating disease of the central nervous system . Memantine has the potential to reduce glutamate toxicity, thereby reducing consequent cognitive impairment, spasticity, and fatigue .", "categories": [] }, { "article_id": 205, "title": "Prevalence of Latent Tuberculosis in the Multiple Sclerosis Clinic and Effect of Multiple Sclerosis Treatment on Tuberculosis Testing", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):26-30. doi: 10.7224/1537-2073.2019-015. Epub 2020 Apr 14.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Patients with a compromised immune system are at risk for converting from latent tuberculosis infection (LTBI) to active tuberculosis (TB) infection. Multiple sclerosis (MS) therapies may put individuals with LTBI at higher risk of TB.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Patients at the Beth Israel Deaconess Medical Center MS Clinic were screened for TB as part of routine testing with the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay (Cellestis Ltd) from 2013 to 2017. Patients were tested either before or during immunomodulatory therapy.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Four of 222 patients (1.8%; 95% CI, 0.1%-3.6%) had positive QFT-GIT results; three patients had risk factors for TB, having emigrated from TB-endemic countries or worked in the health care industry. Twenty-eight of 222 patients (12.6%) had an indeterminate assay result, and 75.0% of these occurred in patients taking dimethyl fumarate. Fingolimod, natalizumab, or anti-CD20 treatments showed 0% to 7.7% indeterminate results.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: The prevalence of LTBI was 1.8% in the Beth Israel Deaconess Medical Center MS Clinic. Not all LTBI cases were associated with known risk factors for TB. Screening for LTBI before starting immunosuppressive agents for MS could help prevent activation of TB. Dimethyl fumarate use is associated with indeterminate QFT-GIT results, possibly due to functional effects on lymphocytes and levels of cytokines, such as interferon gamma. In contrast, fingolimod use was rarely associated with indeterminate QFT-GIT results despite a high rate of lymphopenia in virtually all patients.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658903/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658903</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906031/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906031</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073.2019-015\">10.7224/1537-2073.2019-015</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658903/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [ { "author_id": 240850, "given_name": "Andrew J.", "family_name": "Bouley", "ORCID": null, "country": null }, { "author_id": 240851, "given_name": "Ursela", "family_name": "Baber", "ORCID": null, "country": null }, { "author_id": 240852, "given_name": "Emily", "family_name": "Egnor", "ORCID": null, "country": null }, { "author_id": 240853, "given_name": "Soleil", "family_name": "Samaan", "ORCID": null, "country": null }, { "author_id": 240854, "given_name": "Jacob A.", "family_name": "Sloane", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Prevalence", "Latent Tuberculosis", "the Multiple Sclerosis Clinic", "Effect", "Multiple Sclerosis Treatment", "Tuberculosis Testing" ], "doi": "10.7224/1537-2073.2019-015", "access": "open", "takeaways": " Patients with a compromised immune system are at risk for converting from latent tuberculosis infection (LTBI) to active tuberculosis (TB) infection . Screening for LTBI before starting immunosuppressive agents could help prevent activation of TB .", "categories": [] }, { "article_id": 210, "title": "Identifying Barriers to and Facilitators of Health Service Access Encountered by Individuals with Multiple Sclerosis", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):37-44. doi: 10.7224/1537-2073.2020-026. Epub 2021 Feb 23.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: The symptoms of multiple sclerosis (MS) can be diverse, complex, and progressive, creating a need for frequent and long-standing health care services. The purpose of this scoping review was to identify the barriers people with MS encounter when attempting to access multidisciplinary health services and the reported facilitators for better access to health services.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: The MEDLINE, Embase, and CINAHL databases were searched, without date or geographic restrictions, using the following terms: <i>multiple sclerosis, health services accessibility, health care access, health care delivery,</i> and <i>delivery of health care</i>. After screening based on exclusion criteria, 23 articles were included in the final review.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Five main themes were identified as barriers and facilitators to accessing health services: 1) information (information available to people with MS, health care provider knowledge of and familiarity with MS), 2) interactions (interactions between health care providers and people with MS, social networks and support of people with MS, collaboration among health care providers), 3) beliefs and skills (personal values and beliefs, perceived time to travel to and attend appointments, and self-assessment of symptoms and needs of people with MS), 4) practical considerations (wait times, physical barriers, affordability of services), and 5) nature of MS (complexity and unpredictability of disease symptoms).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: People with MS and their health care providers may benefit from structured and comprehensive MS-specific education to address barriers to accessing health care services. The education can ultimately facilitate the process of addressing unmet health care needs and contribute to a greater quality of life for people with MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658905/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658905</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906029/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906029</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073.2020-026\">10.7224/1537-2073.2020-026</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658905/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [ { "author_id": 240820, "given_name": "Chantel D.", "family_name": "Mayo", "ORCID": null, "country": null }, { "author_id": 240821, "given_name": "Negar", "family_name": "Farzam-kia", "ORCID": null, "country": null }, { "author_id": 240823, "given_name": "Setareh", "family_name": "Ghahari", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Barriers", "Facilitators", "Health Service Access", "Individuals", "Multiple Sclerosis" ], "doi": "10.7224/1537-2073.2020-026", "access": "open", "takeaways": " The symptoms of multiple sclerosis (MS) can be diverse, complex, and progressive, creating a need for frequent and long-standing health care services . Five main themes were identified as barriers and facilitators to accessing health services .", "categories": [] } ] }